HS-10352 in hormone receptor-positive, HER2-negative advanced breast cancer: A phase 1 dose-escalation trial.

Cancer Med · 2023 · PMC10757118 · PMID 38037839

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The AUC ss of the 6 mg QD group was close to that of the 8 mg QD group, and the exposure dose showed a trend of saturation (Figure 2B ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.